Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announce they have completed the sale of Noramco, Extractas Biosciences, and Purisys of the Noramco Group (“Noramco” or the “Company”) to Siegfried Holding AG (SIX: SFZN; “Siegfried”), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals, a leading finished-dose-form CDMO in the United States and Canada with sterile-fill-finish and controlled substance production capabilities.
Read the full article: SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG //
Source: https://www.businesswire.com/news/home/20260501338050/en/SK-Capital-Partners-Completes-Sale-of-Noramco-Extractas-Biosciences-and-Purisys-to-Siegfried-Holding-AG